Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4

Dermatologic Therapy

Volumn 26, Issue 2, 2013, Pages 135-148

  Fischer, Alyssa ^a   Rosen, Alyx C ^a   Ensslin, Courtney J ^a   Wu, Shenhong ^b   Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

cancer; EGFR inhibitor; ipilimumab; pruritus; vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; IPILIMUMAB; VEMURAFENIB;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; HUMAN; MELANOMA; PATHOPHYSIOLOGY; PRURITUS; RASH; XEROSIS;

ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DRUG ERUPTIONS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PRURITUS; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84875852333     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12027     Document Type: Article

References (102)

1. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ,. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol 2011: 23: 343-351.
2. Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011: 50: 129-146.
3. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004: 351: 337-345.
4. Mendelsohn J, Baselga J,. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006: 33: 369-385.
5. PackageInsert. Erbitux (Cetuximab) label: Bristol Myers Squibb. Princeton, NJ: 2012. Accessed November 11, 2012.
6. Giusti RM, Shastri K, Pilaro AM, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008: 14: 1296-1302.
7. PackageInsert. Vectibix (Panitumumab) label: Amgen Pharmaceuticals. Thousand Oaks, CA, 2012. Accessed November 12, 2012.
8. Guttman-Yassky E, Mita A, De Jonge M, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010: 46: 2010-2019.
9. PackageInsert. Tarceva (Erlotinib) label: OSI Pharmaceuticals. Melville, NY, 2010. Accessed November 12, 2012.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010: 363: 711-723.
11. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012: 366: 707-714.
12. Fong L, Small EJ,. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008: 26: 5275-5283.
13. O'Day SJ, Hamid O, Targeting UWJ,. cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007: 110: 2614-2627.
14. PackageInsert. Yervoy (Ipilimumab) Label: Bristol Myers Squibb. Princeton, NJ, 2011. Accessed November 12, 2012.
15. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011: 364: 2507-2516.
16. PackageInsert. Zelboraf (Vemurafenib) Label: Genentech USA, Inc. San Francisco, CA, 2011. Accessed November 12, 2012.
17. Balagula Y, Lacouture ME, Cotliar JA,. Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 2010: 8: 149-161.
18. Gandhi M, Oishi K, Zubal B, Lacouture ME,. Unanticipated toxicities from anticancer therapies: survivors' perspectives. Support Care Cancer 2010: 18: 1461-1468.
19. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010- 06-14-QuickReference-8.5x11.pdf. Accessed February 7, 2013.
20. Fleta-Asin B, Vano-Galvan S, Ledo-Rodriguez A, Truchuelo-Diez M, Jaen-Olasolo P,. Facial acneiform rash associated with sorafenib. Dermatol Online J 2009: 15 (4): 7.
21. Ledezma B,. Ipilimumab for advanced melanoma: a nursing perspective. Oncol Nurs Forum 2009: 36: 97-104.
22. Chren MM, Lasek RJ, Sahay AP, Sands LP,. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001: 5: 105-110.
23. Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 2011: 22: 1367-1373.
24. Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009: 45: 574-578.
25. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011: 29: 3419-3426.
26. Neal JW, Heist RS, Fidias P, et al. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol 2010: 5: 1855-1858.
27. Ramalingam SS, Lee JW, Belani CP, et al. Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). J Clin Oncol 2011: 29: 1709-1714.
28. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007: 110: 581-589.
29. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012: 13: 300-308.
30. Coudert B, Ciuleanu T, Park K, et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012: 23: 388-394.
31. Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012: 77: 556-560.
32. Choi DR, Lee DH, Choi CM, Kim SW, Suh C, Lee JS,. Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study. Anticancer Res 2011: 31: 3457-3462.
33. Lee DH, Kim SW, Suh C, Han YH, Lee JS,. Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer Chemother Pharmacol 2011: 67: 35-39.
34. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011: 29: 1059-1066.
35. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011: 29: 3307-3315.
36. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010: 11: 521-529.
37. Takahashi T, Yamamoto N, Nukiwa T, et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res 2010: 30: 557-563.
38. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP,. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009: 115: 115-121.
39. Kubota K, Nishiwaki Y, Tamura T, et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008: 3: 1439-1445.
40. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008: 26: 4319-4325.
41. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007: 25: 2406-2413.
42. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007: 110: 1059-1067.
43. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006: 24: 4922-4927.
44. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005: 15: 785-792.
45. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005: 23: 6657-6663.
46. Perez-Soler R,. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004: 6 (Suppl 1): S20-S23.
47. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL,. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004: 22: 77-85.
48. Neal JW, Pennell NA, Goodgame BW, et al. A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): toxicity evaluation. J Clin Oncol 2010: 28 (Suppl): abstr 7078.
49. Jasas KV, Fyles A, Elit L, et al. Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148. J Clin Oncol 2004: 22 (Suppl): abstr 5019.
50. Horowitz NS, Olawaiye AB, Borger DR, et al. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol 2012: 127: 141-146.
51. Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012: 30: 3337-3344.
52. Schaake EE, Kappers I, Codrington HE, et al. Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol 2012: 30: 2731-2738.
53. Hecht JR, Mitchell E, Neubauer MA, et al. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 2010: 16: 2205-2213.
54. Muro K, Yoshino T, Doi T, et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2009: 39: 321-326.
55. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007: 25: 1658-1664.
56. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008: 19: 92-98.
57. Yamada YTT, Shirao K, Doi T, et al. Safety and pharmacokinetics (PK) of panitumumab in Japanese patients (pts) with advanced solid malignancies. J Clin Oncol 2007: (Suppl): abstr385. http://www.asco.org/ASCOv2/Meetings/Abstracts? &vmview=abst-detail-view&confID=45&abstractID=10326. Accessed February 7, 2013.
58. Goldinger SM, Rinderknecht JD, Belloni B, Eggmann N, Dummer R,. Cutaneous side effects (cAE) of vemurafenib (V): single-center cohort study of 28 metastatic melanoma (mM) patients (pts). J Clin Oncol 2012: 30 (Suppl): abstr e19017.
59. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011: 29: 489-498.
60. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010: 11: 155-164.
61. Simeone EGG, Romano A, Daponte A, et al. Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival. J Clin Oncol 2012: 30 (Suppl): abstr 8573.
62. Patel T, Yosipovitch G,. Pruritus. In:, ME Lacouture, ed. Dermatologic Principles & Practice in Oncology, 1st ed. Hoboken, NJ: Wiley, 2013: 45-52.
63. Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer 2012: 20: 909-921.
64. Segaert S, Van Cutsem E,. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005: 16: 1425-1433.
65. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H,. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007: 43: 845-851.
66. Roe E, Garcia Muret MP, Marcuello E, Capdevila J, Pallares C, Alomar A,. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006: 55: 429-437.
67. Karthaus MHR, Mineur L, Letocha H, et al. Epidermal growth factor receptor (EGFR) inhibitor-related skin toxicity: review of interim data from a phase II study (2260314) of panitumumab with FOLFIRI in the first-line treat- ment of metastatic colorectal cancer. J Clin Oncol 2009: 27: e20364.
68. Ocvirk J, Cencelj S,. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol 2010: 24: 453-459.
69. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011: 19: 1079-1095.
70. Balagula Y, Wu S, Su X, Lacouture ME,. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Ann Oncol 2011: 22: 2366-2374.
71. Jia Y, Lacouture ME, Su X, Wu S,. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol 2009: 7: 211-217.
72. Su X, Lacouture ME, Jia Y, Wu S,. Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 2009: 77: 124-133.
73. Saltz LB, Meropol NJ, Loehrer PJ, Sr, Needle MN, Kopit J, Mayer RJ,. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004: 22: 1201-1208.
74. Baas JM, Krens LL, Guchelaar HJ, et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat Rev 2012: 38: 505-514.
75. Jatoi A, Green EM, Rowland KM, Jr, Sargent DJ, Alberts SR,. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009: 77: 120-123.
76. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA,. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008: 26: 2350-2357.
77. Cassano N, Tessari G, Vena GA, Girolomoni G,. Chronic pruritus in the absence of specific skin disease: an update on pathophysiology, diagnosis, and therapy. Am J Clin Dermatol 2010: 11: 399-411.
78. Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010: 116: 1767-1775.
79. Cunha PR, Delfini Filho O,. Pruritus: still a challenge. An Bras Dermatol 2012: 87: 735-741.
80. Luu M, Lai SE, Patel J, Guitart J, Lacouture ME,. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 2007: 23: 42-45.
81. Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M,. The neurobiology of itch. Nat Rev Neurosci 2006: 7: 535-547.
82. Stander S, Raap U, Weisshaar E, et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges 2011: 9: 456-463.
83. Jaber SH, Cowen EW, Haworth LR, et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 2006: 142: 166-172.
84. Wang H, Yosipovitch G,. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 2010: 49: 1-11.
85. Lacouture ME,. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006: 6: 803-812.
86. Fallen RS, Terpstra CR, Lima HC,. Immunotherapies in dermatologic disorders. Med Clin North Am 2012: 96: 565-582, x-xi.
87. Gerber PA, Buhren BA, Cevikbas F, Bolke E, Steinhoff M, Homey B,. Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol 2010: 63: 163-165.
88. Schmelz M,. Neuronal sensitivity of the skin. Eur J Dermatol 2011: 21 (Suppl 2): 43-47.
89. Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J,. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol 2013: 27 (1): 11-18.
90. Kern F, Niault T, Baccarini M,. Ras and Raf pathways in epidermis development and carcinogenesis. Br J Cancer 2011: 104: 229-234.
91. Rosen A, Balagula Y, Goldfarb S, Lacouture ME,. Dermatologic adverse events during treatment. In:, Berger AM, Shuster JL, Von Roenn JH, eds. Principles and practice of palliative care and supportive oncology. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012: 4e: 333-347.
92. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010: 28: 1351-1357.
93. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007: 25: 5390-5396.
94. Lynch TJ, Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME,. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007: 12: 610-621.
95. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M,. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009: 16: 16-26.
96. Porzio G, Aielli F, Verna L, et al. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage 2006: 32: 397-398.
97. Vincenzi B, Tonini G, Santini D,. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010: 363: 397-398.
98. Patel T, Ishiuji Y, Yosipovitch G,. Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol 2007: 57: 873-878.
99. Afshar M, Kotol P, Miller J, Gallo R, Hata T,. The effect of pimecrolimus on innate immunity in subjects with atopic dermatitis: a double-blind, randomized, vehicle-controlled study. Br J Dermatol 2013: 168 (2): 426-428.
100. Scope A, Lieb JA, Dusza SW, et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009: 61: 614-620.
101. Gupta AK, Chow M,. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003: 17: 493-503.
102. Balagula E, Lacouture M,. Dermatologic toxicities. In:, Olver IN, ed. The MASCC textbook of cancer supportive care and survivorship. New York, Springer, 2011: 361-380.